放射性リガンド療法市場レポート：動向、予測、競合分析 (2030年まで)

放射性リガンド療法の動向と予測

世界の放射性リガンド療法市場は、病院・診療所と診断センター市場に機会があり、将来性が期待されます。世界の放射性リガンド療法市場は、2024年から2030年までのCAGRが5.0%で、2030年までに推定138億米ドルに達すると予想されます。この市場の主な促進要因は、がん罹患率の上昇と効果的な治療に対する需要の高さです。

• Lucintel社は、同位体カテゴリーでは、がん診断の需要が高いため、予測期間中もフッ素-18が最大セグメントであり続けると予測しています。
• 最終用途カテゴリーでは、座りっぱなしのライフスタイルの普及と世界のがん患者の増加により、病院が引き続き最大セグメントとなります。
• 地域別では、北米が、がん専門病院や研究センターの存在、地域全体のがん罹患率の上昇により、予測期間中も最大地域であり続けると思われます。

放射性リガンド療法市場の戦略的成長機会

放射性リガンド療法市場は、技術の進歩やがん治療における標的治療の受け入れ拡大により、さまざまな機会をもたらしています。これらの機会を活用することは、事業の進展と市場の拡大につながります。

• 前立腺がん治療：前立腺がんの罹患率の増加により、Pluvictoのような標的治療薬が引き続き人気を集めています。研究開発活動のさらなる拡大とこの分野での事業拡大により、より効果的な治療へのニーズに対応しつつ、大きな成長機会がもたらされます。
• 神経内分泌腫瘍：神経内分泌腫瘍における放射性リガンド療法のための予後診断アプローチは、規制と市場開拓の成功により、さらなる開発と市場化が可能であることが示されました。この好機は、対象集団を拡大することで企業の収益ギャップを埋めるものです。
• 併用療法：放射性リガンド療法を免疫療法や化学療法と組み合わせることで、治療をより効果的かつ長続きさせ、耐性を回避できる可能性があります。これは研究と市場成長の新たな機会を提供し、患者と治療法の双方に利益をもたらします。
• 新興市場：潜在市場における放射性リガンド療法の出現は、高度な薬物療法に対する需要の高まりに対応するものです。この機会は世界市場規模の拡大に役立ち、新たな患者グループへのアクセスを提供します。
• 高度な画像診断の統合：放射性リガンド療法は、PETやSPECTなどの高度なイメージング技術を取り入れることで、治療精度と管理の面で大幅に改善されます。この機会は、より優れた治療選択肢を提供することで市場成長を実現します。

前立腺がん、神経内分泌腫瘍、併用療法、新興市場、および高度画像統合には、市場成長のために利用できる戦略的な市場成長機会があります。これらの機会は、放射性リガンド療法市場における潜在的な拡大と技術強化を後押しします。

放射性リガンド療法市場の促進要因・課題

放射性リガンド療法市場の指針は、いくつかの規制、技術、経済の促進要因・課題によって定義されます。これらの要因に対処することが、市場の成長と革新には不可欠です。

放射性リガンド療法市場の促進要因

• 技術進歩：新しい技術が開発されるにつれ、放射性リガンド療法はより効率的で正確なものとなります。新しい製造プロセスや高度なイメージング技術の発見は治療効果を向上させ、放射性リガンド療法の範囲を広げることで市場成長に貢献します。
• がん診断の増加：がん罹患率の増加は標的治療薬の需要を高めます。がんの罹患率の増加は、先進的な放射性リガンド療法の商業化を加速し、アンメット・メディカル・ニーズを満たすためのさらなる研究開発を支援します。
• 特定の医薬品に対する規制当局の承認：新しい治療法に対する規制当局の承認が早まることで、新しい放射性リガンド療法法の開発とイントロダクションが効率化されます。このプロセスは、治療開発において望ましい結果を促進することにより、市場の成長を促進します。
• 研究開発への投資の増加：放射性リガンド療法の進歩には、企業による多くの共同努力が貢献しています。このような共同研究は研究開発を強化し、新たなアプリケーションの提案やより効率的な治療につながります。
• よりターゲットを絞ったがん治療の開発：個別化医療に向けた動きは、個々の患者に対する放射性リガンド療法の開発を可能にしています。これにより治療成績が向上し、患者の具体的なニーズに応えることで市場の拡大につながります。

放射性リガンド療法市場の課題

• 高い開発コスト：新しい治療法や技術の開発には高いコストがかかるため、進歩の妨げになる可能性があります。企業が競争力を維持するためには、コスト管理と投資計画が不可欠です。
• 規制上の障害：薬事規制への対応は困難で時間がかかります。企業は、新しい治療法の承認プロセスを迅速化するために、進化する規制について常に最新情報を入手する必要があります。
• 市場競争：市場競争は市場シェアや利益に影響を与える可能性があります。企業は、競争に勝ち残るために技術革新を行い、強力な臨床エビデンスを提供し、市場での地位を高めるためにパートナーシップを結ぶ必要があります。

放射性リガンド療法市場は、技術の進歩、がん罹患率の増加、規制当局の承認、研究開発投資、個別化医療への動向などによって牽引されています。しかし、高い開発コスト、規制上のハードル、市場競争に対処し、成長とイノベーションを確保する必要があります。

目次

第1章 エグゼクティブサマリー

第2章 世界の放射性リガンド療法市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 市場動向と予測分析 (2018年～2030年)

• マクロ経済動向 (2018～2023年) と予測 (2024～2030年)
• 世界の放射性リガンド療法市場の動向 (2018～2023年) と予測 (2024～2030年)
• 世界の放射性リガンド療法市場：同位体別
  • フッ素-18
  • ガリウム-68
  • ルテチウム-177
  • その他
• 世界の放射性リガンド療法市場：標的受容体別
  • 前立腺特異膜抗原
  • ソマトスタチン受容体
  • 上皮成長因子受容体
  • その他
• 世界の放射性リガンド療法市場：適応症別
  • 前立腺がん
  • 神経内分泌腫瘍
  • 乳がん
  • その他
• 世界の放射性リガンド療法市場：最終用途別
  • 病院・クリニック
  • 診断センター
  • その他

第4章 地域別の市場動向と予測分析 (2018年～2030年)

• 世界の放射性リガンド療法市場：地域別
• 北米の放射性リガンド療法市場
• 欧州の放射性リガンド療法市場
• アジア太平洋の放射性リガンド療法市場
• その他地域の放射性リガンド療法市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 世界の放射性リガンド療法市場の成長機会：同位体別
  • 世界の放射性リガンド療法市場の成長機会：標的受容体別
  • 世界の放射性リガンド療法市場の成長機会：適応症別
  • 世界の放射性リガンド療法市場の成長機会：最終用途別
  • 世界の放射性リガンド療法市場の成長機会：地域別
• 世界の放射性リガンド療法市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界の放射性リガンド療法市場の生産能力拡大
  • 世界の放射性リガンド療法市場における企業合併・買収 (M&A)、合弁事業
  • 認証とライセンシング

第7章 主要企業のプロファイル

• Novartis
• POINT Biopharma Global
• Molecular Partners
• Telix Pharmaceuticals
• Fusion Pharma
• Lantheus Holdings
• Curium
• Precrix
• Orano
• Artios Pharma

Radioligand Therapy Trends and Forecast

The future of the global radioligand therapy market looks promising with opportunities in the hospitals & clinics and diagnostic center markets. The global radioligand therapy market is expected to reach an estimated $13.8 billion by 2030 with a CAGR of 5.0% from 2024 to 2030. The major drivers for this market are rising cancer rates and the high demand for effective treatment.

• Lucintel forecasts that, within the isotope category, fluorine-18 will remain the largest segment over the forecast period due to the high demand for cancer diagnosis.
• Within this end-use category, hospitals will remain the largest segment due to the increasing prevalence of a sedentary lifestyle and the growing cases of cancer globally.
• In terms of regions, North America will remain the largest region over the forecast period due to the presence of specialized cancer hospitals and research centers, as well as the rising incidences of cancer across the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Radioligand Therapy Market

The radioligand therapy market underscores the changes brought about by technology, clinical development, and patient treatment. These trends are transforming the landscape of chemotherapy and broadening the range of indications for radioligand therapies.

• Increased Focus on Personalized Medicine: Tailoring the pharmacological agents used in radioligand therapy to the patient's tumor markers and genetic makeup adds another dimension to the personalized medicine aspect of radioligand therapy. This also leads to better responses and fewer side effects, which promote the use of personalized therapies, thereby increasing the market potential for such therapies.
• Progress in Radiopharmaceutical Manufacturing: Increases in automation and better radiolabeling technologies make these production processes more efficient and amenable to scaling up, increasing the availability of radioligand therapies for patients. Such advancements meet the increasing market need for quality radiopharmaceuticals and simplify treatment procedures.
• Increase in Clinical Trials and Research: The expansion of clinical trials enhances the discovery of new treatments with radioligands as well as new markets for older drugs. Innovations and contributions toward radioligand therapy, anchored in evidence-based research, increase penetration and acceptance of the therapy in the market and among the population at large.
• Use of Other Imaging Approaches: Advanced imaging techniques, such as combining SPECT or PET with radioligands, enable researchers to monitor responses and locate cancer sites in real-time during the course of therapy, enhancing the accuracy of radioligand therapies. This trend improves patient management and outcomes as it increases treatment accuracy and, therefore, efficacy.
• Improvement in International Networking and Cooperation: With the central goal of optimizing research and clinical development of radioligand therapies, global partnerships enhance the movement of knowledge, resources, and technologies. The benefits of these collaborations include access to know-how and creativity, which fosters market development and increases the availability of new therapies.

The emerging themes of personalized medicine, new frontiers in radiopharmaceutical production, clinical research expansion, incorporation with imaging, and international collaborations are game-changers in the radioligand therapy market. These trends stimulate development, increase efficacy, and elevate the feasibility of targeted cancer treatment options.

Recent Developments in the Radioligand Therapy Market

The recent developments in radioligand therapy, which also include commercialization activities, emphasize technological advancements, clinical application patterns, and marketing trends. These developments create avenues for new research and further descriptive development of radioligand therapy in the management of localized cancer.

• FDA Approvals of Novel Therapies: This will broaden the scope of available therapies for patients suffering from neuroendocrine tumors and prostate cancer. It also opens up new market avenues and facilitates the innovation process in radioligand therapy by increasing the types of treatments available.
• Development of New Procedures for the Production of Radiopharmaceuticals: Advances in production technology contribute to the optimal utilization and bulk production of radiopharmaceuticals. These improvements benefit the expansion of the market, where the demand for higher-quality radioligand therapies continues to grow.
• Broadening of Clinical Trials: Expanding the scope of clinical trials accelerates the formulation of medicines and substantiates the claims made about current medications. This development enables further market growth through research and improvement of therapy modalities.
• Inclusion of Improved Imaging Techniques: The use of advanced imaging techniques adds to the accuracy and effectiveness of radioligand therapies. In this development, treatment response and tumor localization during treatment are monitored, improving patient management and outcomes.
• Collaborations and Partnerships Around the Globe: Partnerships help pool skills and assets, which in turn accelerate the development and marketing of radioligand therapies. These collaborations consolidate the global market and encourage creativity by working together.

In the last one and a half years, advances in FDA approvals, production, clinical trials, incorporation of imaging, and international collaborations have greatly influenced the radioligand therapy market. These advancements foster innovation, improve treatment effectiveness, and increase the potential for commercialization of products, thus defining future targeted cancer therapies.

Strategic Growth Opportunities for Radioligand Therapy Market

The radioligand therapy market presents various opportunities due to technological advancements and the growing acceptance of targeted therapy for cancer treatment. Taking advantage of these opportunities will help in business advancement and market expansion.

• Prostate Cancer Treatment: Targeted treatments like Pluvicto continue to gain traction due to the increasing incidence rates of prostate cancer. Further expansion of R&D activities and a larger footprint in this area present significant growth opportunities while addressing the need for more effective treatments.
• Neuroendocrine Tumors: Successful regulation and market access demonstrate that theragnostic approaches for radioligand therapy in neuroendocrine tumors can be further developed and marketed. This opportunity fills revenue gaps for businesses by expanding target populations.
• Combination Therapies: Combining radioligand therapies with immunotherapy or chemotherapy could make treatment more effective and lasting while avoiding resistance. This offers new opportunities for research and market growth, benefiting both patients and their treatments.
• Emerging Markets: The emergence of radioligand therapies in latent markets meets the increasing demand for advanced medication. This opportunity helps expand the size of the global market and provides access to new patient groups.
• Advanced Imaging Integration: Radioligand therapies are significantly improved in terms of treatment accuracy and management by incorporating advanced imaging techniques, such as PET and SPECT. This opportunity achieves market growth by providing better treatment options.

There are strategic market growth opportunities in prostate cancer, neuroendocrine tumors, combination therapies, emerging markets, and advanced imaging integration that can be exploited for market growth. These opportunities encourage potential expansion and technology enhancement in the radioligand therapy market.

Radioligand Therapy Market Driver and Challenges

The guiding factors for the radioligand therapy market are defined by several regulatory, technological, and economic drivers and challenges. Addressing these factors is essential for growth and innovation in the marketplace.

Drivers of the Radioligand Therapy Market:

• Technological Advancements: As new techniques are developed, radioligand therapies become more efficient and accurate. The discovery of new production processes and advanced imaging techniques improves treatment efficacy and contributes to market growth by broadening the scope of radioligand therapies.
• Increasing Cancer Diagnoses: The rising prevalence of cancer enhances the demand for targeted therapies. The growing incidence of cancer accelerates the commercialization of advanced radioligand therapies and supports further research and development to meet unmet medical needs.
• Regulatory Approvals for Certain Drugs: Faster regulatory approvals for new therapies help streamline the development and introduction of new radioligand treatments. This process fosters market growth by promoting the desired outcomes in treatment development.
• Increased Investment in R&D: Many collaborative efforts by companies have contributed to advancements in radioligand therapy. These collaborations enhance research and development, leading to proposed new applications and more efficient treatments.
• Development of More Targeted Treatments for Cancer: The movement toward personalized medicine is enabling the development of radioligand therapies for individual patients. This improves treatment outcomes and helps expand the market by meeting the specific needs of patients.

Challenges in the Radioligand Therapy Market:

• High Development Costs: The high costs associated with developing new therapies and technologies may hinder progress. Cost control and investment planning are essential for companies to stay competitive.
• Regulatory Roadblocks: Navigating regulatory requirements can be challenging and time-consuming. Companies must stay updated on evolving regulations to expedite approval processes for new therapies.
• Market Competition: Competition in the market may impact market share and profits. Companies must innovate and provide strong clinical evidence to stay ahead of the competition and engage in partnerships that enhance their market position.

The radioligand therapy market is driven by technological advancements, increasing cancer prevalence, regulatory approvals, R&D investment, and trends toward personalized medicine. However, high development costs, regulatory hurdles, and market competition must be addressed to ensure growth and innovation.

List of Radioligand Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radioligand therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radioligand therapy companies profiled in this report include-

• Novartis
• POINT Biopharma Global
• Molecular Partners
• Telix Pharmaceuticals
• Fusion Pharma
• Lantheus Holdings
• Curium
• Precrix
• Orano
• Artios Pharma

Radioligand Therapy by Segment

The study includes a forecast for the global radioligand therapy by isotope, targeted receptor, indication, end use, and region.

Radioligand Therapy Market by Isotope [Analysis by Value from 2018 to 2030]:

• Fluorine - 18
• Gallium - 68
• Lutetium - 177
• Others

Radioligand Therapy Market by Targeted Receptor [Analysis by Value from 2018 to 2030]:

• Prostate-Specific Membrane Antigen
• Somatostatin Receptor
• Epidermal Growth Factor Receptor
• Others

Radioligand Therapy Market by Indication [Analysis by Value from 2018 to 2030]:

• Prostate Cancer
• Neuroendocrine Tumors
• Breast Cancer
• Others

Radioligand Therapy Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals & Clinics
• Diagnostic Centers
• Others

Radioligand Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Radioligand Therapy Market

Recent developments in the radioligand therapy market include advances in technology, registration, and clinical practice. The growing trend among patients toward personalized medicine and targeted techniques is filling the gap created by recent activity in the field of radioligand therapies in countries like the United States, China, Germany, India, and Japan.

• United States: The US market for radioligand therapy is growing rapidly due to new FDA treatment approvals and the expansion of clinical trials. Recent developments include the release of promising drugs, such as Lutathera for treating neuroendocrine tumors and Pluvicto for treating prostate cancer. There is also a focus on improving technologies for radiopharmaceutical production and exploring new therapy combinations to improve treatment efficacy.
• China: China is making significant progress in radioligand treatment, focusing on building a local manufacturing base and expanding clinical trials. Recently, partnerships have been formed between Chinese pharmaceutical companies and international firms to develop new radioligand products. The country is also implementing regulatory schemes to facilitate approvals for radioligand therapies to meet the growing demand for tailored cancer treatments.
• Germany: Germany remains a leader in the radioligand therapy market, making continuous strides in research and development. German institutions are involved in clinical trials for new therapeutic radioligands targeting various cancers, including prostate and neuroendocrine tumors. The country is also enhancing its radiopharmaceutical manufacturing infrastructure and improving treatment control using advanced imaging techniques.
• India: The radioligand therapy market in India is evolving as the population becomes more engaged in oncology and personalized medicine. Clinical trials focusing on new radioligand therapies and global partnerships with research institutions have been established. The focus is on increasing the availability of new radiopharmaceuticals and expanding the use of existing ones to meet the growing patient pool.
• Japan: Japan is also progressing in the radioligand therapy market, with new treatment approvals and technological innovations. Japanese oncology organizations are developing new radioligand therapies and improving production technologies for both domestic use and export. The country is also increasing funding for research to find more indications and enhance existing treatments.

Features of the Global Radioligand Therapy Market

Market Size Estimates: Radioligand therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Radioligand therapy market size by various segments, such as by isotope, targeted receptor, indication, end use, and region in terms of value ($B).

Regional Analysis: Radioligand therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different isotope, targeted receptor, indications, end uses, and regions for the radioligand therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radioligand therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the radioligand therapy market by isotope (fluorine - 18, gallium - 68, lutetium - 177, and others), targeted receptor (prostate-specific membrane antigen, somatostatin receptor, epidermal growth factor receptor, and others), indication (prostate cancer, neuroendocrine tumors, breast cancer, and others), end use (hospitals & clinics, diagnostic centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Radioligand Therapy Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Radioligand Therapy Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Radioligand Therapy Market by Isotope
  • 3.3.1: Fluorine - 18
  • 3.3.2: Gallium - 68
  • 3.3.3: Lutetium - 177
  • 3.3.4: Others
• 3.4: Global Radioligand Therapy Market by Targeted Receptor
  • 3.4.1: Prostate-specific Membrane Antigen
  • 3.4.2: Somatostatin Receptor
  • 3.4.3: Epidermal Growth Factor Receptor
  • 3.4.4: Others
• 3.5: Global Radioligand Therapy Market by Indication
  • 3.5.1: Prostate Cancer
  • 3.5.2: Neuroendocrine Tumors
  • 3.5.3: Breast Cancer
  • 3.5.4: Others
• 3.6: Global Radioligand Therapy Market by End Use
  • 3.6.1: Hospitals & Clinics
  • 3.6.2: Diagnostic Centers
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Radioligand Therapy Market by Region
• 4.2: North American Radioligand Therapy Market
  • 4.2.1: North American Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
  • 4.2.2: North American Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
• 4.3: European Radioligand Therapy Market
  • 4.3.1: European Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
  • 4.3.2: European Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
• 4.4: APAC Radioligand Therapy Market
  • 4.4.1: APAC Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
  • 4.4.2: APAC Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
• 4.5: ROW Radioligand Therapy Market
  • 4.5.1: ROW Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
  • 4.5.2: ROW Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Radioligand Therapy Market by Isotope
  • 6.1.2: Growth Opportunities for the Global Radioligand Therapy Market by Targeted Receptor
  • 6.1.3: Growth Opportunities for the Global Radioligand Therapy Market by Indication
  • 6.1.4: Growth Opportunities for the Global Radioligand Therapy Market by End Use
  • 6.1.5: Growth Opportunities for the Global Radioligand Therapy Market by Region
• 6.2: Emerging Trends in the Global Radioligand Therapy Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Radioligand Therapy Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radioligand Therapy Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Novartis
• 7.2: POINT Biopharma Global
• 7.3: Molecular Partners
• 7.4: Telix Pharmaceuticals
• 7.5: Fusion Pharma
• 7.6: Lantheus Holdings
• 7.7: Curium
• 7.8: Precrix
• 7.9: Orano
• 7.10: Artios Pharma